Java Development Kit (JDK) 26, a planned update to standard Java due March 17, 2026, has reached its second release candidate (RC) stage. The RC is open for critical bug fixes, with the feature set ...

RISING health care costs could lead to tighter government price controls, a Fitch Group unit said, creating headwinds for pharmaceutical companies and speeding up a shift toward cheaper generics. “The ...

Feb 25 - Zydus Lifesciences (ZYDU.NS), opens new tab will launch generic versions of semaglutide injections for obesity and diabetes in India after patent expiry of the Ozempic active ingredient in ...

Sales of weight loss medicines like Ozempic and Mounjaro have skyrocketed in South Africa in recent years. However, they remain too expensive for most people who might benefit from the jabs. Spotlight ...

Indian drugmaker Dr Reddy’s Laboratories hopes to launch a generic version of Novo Nordisk’s blockbuster weight-loss drug ‌Wegovy at a competitive price that could be up to 60% lower than the branded ...

In a significant patent skirmish for the Australian biotech and pharmaceutical sector, AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has secured a Federal Court ruling that blocks local generics maker ...

After manufacturing the antibiotic Rocephin for four decades—and developing it into one of the company’s first blockbuster medicines—Roche is looking to divest the treatment and its production ...

A close look at recent personnel moves at drugmakers shows the rise of executives with "sales backgrounds." As the government pushes to cut prices of generics, companies appear to be strengthening ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Oral anti-obesity formulations will be the next growth lever in Danish drugmaker Novo Nordisk's India strategy, following the 2025 launches of its blockbuster diabetes and obesity brands Ozempic and ...